HQL: abrdn Life Sciences Investors
Performance
Watchlist
Select an item
Summary
HQL at a glance
HQL returned +14.68% over the past year and +8.30% a year over five years. Its worst drop in that year was -23.87%, smaller than 7% of closed-end funds on Redstone, and its Sharpe ratio of 0.53 beats 81% of closed-end funds on Redstone. It yields 12.81%.
Ranking
How HQL ranks
Current Drawdown
-20.65%
Rolling Volatility
35.17%
Dividends
HQL dividends
Yield
12.81%
Paid, past year
$2.24
Pays
Quarterly
Growth a year
+10.2%
Per share, by year
Yearly return over 5 years
HQL paid $2.24 a share over the past year, every quarter. Its yearly rate rose from $1.36 in 2022 to $1.82 in 2025, 10.2% a year. With dividends reinvested it returned +8.30% a year over five years, against -3.13% on price alone.
›All 20 payments since Nov 23, 2021
- Aug 24, 2026$0.62
- May 21, 2026$0.56
- Feb 20, 2026$0.56
- Nov 21, 2025$0.50
- Aug 22, 2025$0.42
- May 22, 2025$0.43
- Feb 21, 2025$0.47
- Nov 21, 2024$0.50
- Aug 23, 2024$0.49
- May 22, 2024$0.48
- Feb 21, 2024$0.39
- Nov 21, 2023$0.30
- Aug 24, 2023$0.32
- May 24, 2023$0.32
- Feb 24, 2023$0.33
- Nov 23, 2022$0.31
- Aug 25, 2022$0.31
- May 26, 2022$0.35
- Feb 24, 2022$0.39
- Nov 23, 2021$0.42
Metrics
Risk Indicators
Profile
About HQL
The Fund's investment objective is to seek long-term capital appreciation by investing primarily in securities of life sciences companies.
From its annual report, filed Dec 8, 2025- Category
- Health Care
- Expense ratio
- 1.24%
- Market cap
- $532M
- Listed
- May 1992
Comparisons